Company news

Replimune Group, Inc. news in 2024

Replimune Group, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 22, 2024

Replimune Announces Proposed Public Offering

November 24, 2024

Replimune Announces Pricing of Upsized Public Offering

November 24, 2024

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

November 20, 2024

Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

November 11, 2024

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

November 8, 2024

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

October 29, 2024

Replimune to Present at Two Upcoming Investor Conferences

September 30, 2024

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

September 14, 2024

Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024

September 8, 2024

Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024

August 21, 2024

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

August 12, 2024

Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update

August 7, 2024

Replimune Announces $100 Million Private Placement Financing

June 12, 2024

Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 6, 2024

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

June 5, 2024

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

June 2, 2024

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2024

Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update

May 15, 2024

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

April 6, 2024

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

March 25, 2024

Replimune to Present at the American Association for Cancer Research Annual Meeting 2024

March 5, 2024

Replimune to Present at Three Upcoming Investor Conferences

March 4, 2024

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

February 7, 2024

Decks in 2024